AR035340A1 - Compuestos de succinimida heterociclicos fusionados y analogos de los mismos, las composiciones farmaceuticas que los contienen y metodos para preparar dichos compuestos - Google Patents
Compuestos de succinimida heterociclicos fusionados y analogos de los mismos, las composiciones farmaceuticas que los contienen y metodos para preparar dichos compuestosInfo
- Publication number
- AR035340A1 AR035340A1 ARP010103101A ARP010103101A AR035340A1 AR 035340 A1 AR035340 A1 AR 035340A1 AR P010103101 A ARP010103101 A AR P010103101A AR P010103101 A ARP010103101 A AR P010103101A AR 035340 A1 AR035340 A1 AR 035340A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- alkyl
- cycloalkenyl
- cycloalkyl
- heterocycle
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Addiction (AREA)
- Transplantation (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se describen compuestos cíclicos fusionados, útiles en el tratamiento de condiciones asociadas con receptores de hormonas nucleares, tales como el cáncer y trastornos inmunes, las composiciones farmacéuticas que contienen tales compuestos y métodos para preparar dichos compuestos. Dichos compuestos tienen la fórmula (1) en donde los símbolos tienen los siguientes significados y son, cada vez que ocurren, seleccionados independientemente: donde G es un grupo arilo o heterociclo, donde el grupo es mono- o policíclico, y el cual está opcionalmente sustituido en una o más posiciones; Z1 es O, S, NH, o NR6; Z2 es O, S, NH, o NR6; A1 es CR7 o N; A2 es CR7 o N; Y' es J-J'-J'' donde J es (CR7R7')n y n = 0-3; J' es un enlace o O, S, S=O, SO2, NH, NR7, CR7R7' R2P=O, R2P=S, R2OP=O, R2NHP=O, OP=OOR2, OP=ONHR2, OSO2, NHNH, NHNR6, NR6NH, N=N, cicloalquilo o cicloalquilo sustituido, cicloalquenilo o cicloalquenilo sustituido,, heterociclo o heterociclo sustituido, y J'' es (CR7R7')n y n = 0-3, donde Y no es un enlace; y W' es CR7R7' - CR7R7', CR7R7'-C=O, NR9-CR7R7', N=CR8, N=N, NR9-NR9', cicloalquilo o cicloalquilo sustituido, cicloalquenilo o cicloalquenilo sustituido, heterociclo o heterociclo sustituido, o arilo o arilo sustituido, donde cuando W no es NR9-CR7R7', N=CR8, N=N, NR9-NR9', o heterociclo o heterociclo sustituido, entonces J' debe ser O, S, S=O, SO2, NH, NR7, OP=OOR2, OP=ONHR2, OSO2, NHNH, NHNR6, NR6NH, o N=N; Y'es NR7-CR7R7' y W' es CR8=CR8; o, de manera alternativa; Y' es CR7R7'-C=O y W' es NR9-CR7R7'; Q1 es H, alquilo o alquilo sustituido, alquenilo o alquenilo sustituido,, cicloalquilo o cicloalquilo sustituido, cicloalquenilo o cicloalquenilo sustituido, heterocicloalquilo o heterocicloalquilo sustituido, arilalquilo o arilalquilo sustituido, alquinilo o alquinilo sustituido, arilo o arilo sustituido, heterociclo o heterociclo sustituido, halo, CN, R1OC=O, R4C=O, R5R6NC=O, HOCR7R7', nitro, R1OCH2, R1O, NH2, C=OSR1, SO2R1 o NR4R5; Q2 es H, alquilo o alquilo sustituido, alquenilo o alquenilo sustituido, cicloalquilo o cicloalquilo sustituido, cicloalquenilo o cicloalquenilo sustituido, heterocicloalquilo o heterocicloalquilo sustituido, arilalquilo o arilalquilo sustituido, alquinilo o alquinilo sustituido, arilo o arilo sustituido, heterociclo o heterociclo sustituido, halo, CN, R1OC=O, R4C=O, R5R6NC=O, HOCR7R7', nitro, R1OCH2, R1O, NH2, C=OSR1, SO2R1 o NR4R5; L es un enlace, (CR7R7')n, NH, NR5 o NR5(CR7R7')n, donde n = 0-3; R1 y R1' son cada uno independientemente H, alquilo o alquilo sustituido, cicloalquilo o cicloalquilo sustituido, cicloalquenilo o cicloalquenilo sustituido, heterociclo o heterociclo sustituido, cicloalquilalquilo o cicloalquilalquilo sustituido, cicloalquenilalquilo o cicloalquenilalquilo sustituido, heterocicloalquilo o heterocicloalquilo sustituido, arilo o arilo sustituido, arilalquilo o arilalquilo sustituido; R2 es alquilo o alquilo sustituido, cicloalquilo o cicloalquilo sustituido, cicloalquenilo o cicloalquenilo sustituido, heterociclo o heterociclo sustituido, cicloalquilalquilo o cicloalquilalquilo sustituido, cicloalquenilalquilo o cicloalquenilalquilo sustituido, heterocicloalquilo o heterocicloalquilo sustituido, arilo o arilo sustituido, arilalquilo o arilalquilo sustituido, R3 y R3' son cada uno independientemente H, alquilo o alquilo sustituido, cicloalquilo o cicloalquilo sustituido, cicloalquenilo o cicloalquenilo sustituido, heterociclo o heterociclo sustituido, cicloalquilalquilo o cicloalquilalquilo sustituido, cicloalquenilalquilo o cicloalquenilalquilo sustituido, heterocicloalquilo o heterocicloalquilo sustituido, arilo o arilo sustituido, arilalquilo o arilalquilo sustituido, halo, CN, hidroxilamina, hidroxamida, alcoxi o alcoxi sustituido, amino, NR1R2, tiol, alquiltio o alquiltio sustituido; R4 es H, alquilo o alquilo sustituido, cicloalquilo o cicloalquilo sustituido, cicloalquenilo o cicloalquenilo sustituido, heterociclo o heterociclo sustituido, cicloalquilalquilo o cicloalquilalquilo sustituido, cicloalquenilalquilo o cicloalquenilalquilo sustituido, heterocicloalquilo o heterocicloalquilo sustituido, arilo o arilo sustituido, arilalquilo o arilalquilo sustituido, R1C=O, R1NHC=O, SO2OR1 o SO2NR1R1'; R5 es alquilo o alquilo sustituido, cicloalquilo o cicloalquilo sustituido, cicloalquenilo o cicloalquenilo sustituido, heterociclo o heterociclo sustituido, cicloalquilalquilo o cicloalquilalquilo sustituido, cicloalquenilalquilo o cicloalquenilalquilo sustituido, heterocicloalquilo o heterocicloalquilo sustituido, arilo o arilo sustituido, arilalquilo o arilalquilo sustituido, R1C=O, R1NHC=O, SO2R1, SO2OR1 o SO2NR1R1'; R6 es alquilo o alquilo sustituido, cicloalquilo o cicloalquilo sustituido, cicloalquenilo o cicloalquenilo sustituido, heterociclo o heterociclo sustituido, cicloalquilalquilo o cicloalquilalquilo sustituido, cicloalquenilalquilo o cicloalquenilalquilo sustituido, heterocicloalquilo o heterocicloalquilo sustituido, arilo o arilo sustituido, arilalquilo o arilalquilo sustituido, CN, OH, OR1, R1C=O, R1NHC=O, SO2R1, SO2OR1 o SO2NR1R1'; R7 y R7' son cada uno independientemente H, alquilo o alquilo sustituido, alquenilo o alquenilo sustituido, cicloalquilo o cicloalquilo sustituido, cicloalquenilo o cicloalquenilo sustituido, heterociclo o heterociclo sustituido, cicloalquilalquilo o cicloalquilalquilo sustituido, cicloalquenilalquilo o cicloalquenilalquilo sustituido, heterocicloalquilo o heterocicloalquilo sustituido, arilo o arilo sustituido, arilalquilo o arilalquilo sustituido, halo, CN, OR1, nitro, hidroxilamina, hidroxilamida, amino, NHR4, NR2R5, NOR1, tiol, alquiltio o alquiltio sustituido, R1C=O, R1OC=O, R1NHC=O, SO2R1, SOR1, PO3R1R1', R1R1'NC=O, C=OSR1, SO2R1, SO2OR1 o SO2NR1R1'; o donde A1 o A2 contienen un grupo R7 y W contiene un grupo R7, el grupo R7 de los grupos A1 o A2 y W, juntos forman un anillo heterocíclico; R8 y R8' son cada una independientemente H, alquilo o alquilo sustituido, alquenilo o alquenilo sustituido, cicloalquilo o cicloalquilo sustituido, cicloalquenilo o cicloalquenilo sustituido, heterociclo o heterociclo sustituido, cicloalquilalquilo o cicloalquilalquilo sustituido, cicloalquenilalquilo o cicloalquenilalquilo sustituido, heterocicloalquilo o heterocicloalquilo sustituido, arilo o arilo sustituido, arilalquilo o arilalquilo sustituido, nitro, halo, CN, OR1, amino, NHR4, NR2R5, NOR1, alquiltio o alquiltio sustituido, C=OSR1, R1OC=O, R1C=O, R1NHC=O, R1R1'NC=O, SO2OR1, S=OR1, SO2R1, PO3R1R1', o SO2NR1R1'; y R9 y R9' son cada uno independientemente H, alquilo o alquilo sustituido, alquenilo o alquenilo sustituido, cicloalquilo o cicloalquilo sustituido, cicloalquenilo o cicloalquenilo sustituido, heterociclo o heterociclo sustituido, cicloalquilalquilo o cicloalquilalquilo sustituido, cicloalquenilalquilo o cicloalquenilalquilo sustituido, heterocicloalquilo o heterocicloalquilo sustituido, arilo o arilo sustituido, arilalquilo o arilalquilo sustituido, CN, OH, OR1, R1C=O, R1OC=O, R1NCH=O, SO2OR1 o SO2NR1R1'; con la condición de que: (1) cuando Y' es -O-, Q1 y Q2 son hidrógeno, Z1 y Z2 son O, W' es CH2-CH2-, y A1 y A2 son CH, entonces G-L no es fenilo o fenilo monosustituido o fenilo el cual está sustituido con dos o más de los siguientes grupos: metoxi, halo, NO2, metilo, CH3-S-, OH, CO2H, trifluorometilo, -C(O)-C6H5, NH2, 4-7-epoxi, hexahidro-1H-isoindol-1,3(2H)diona, o -C(O)-CH3; (2) cuando Y' es -O-, Q1 y Q2 son hidrógeno, Z1 y Z2 son O, W' es CH2-CH2- y uno de A1 y A2 son CH y el otro es CR7, y entonces G-L no es fenilo no sustituido; (3) cuando Y' es -O-, Q1 y Q2 son hidrógeno, Z1 y Z2 son O, W' es CH2-CH2, y uno de A1 y A2 es CH y el otro es C-CH3, entonces G-L no es fenilo sustituido con cloro y/o metilo, (4) cuando Y' es -O- o -S-, Q1 y Q2 son hidrógeno, Z1 y Z2 son O, W' es CH2-CH2, y uno de A1 y A2 es CH y el otro es CH o C-alquilo, entonces G-L es piperacin-alquil- sustituido del átomo de N o imidazolidin-alquil- sustituido del átomo de N; (5) cuando Y' es -O-; Q1 y Q2 son hidrógeno, Z1 y Z2 son O, W' es CH2-CH2, y A1 y A2 son CH, entonces G-L no es oxazol o triazol; (6) cuando Y' es -O-; Q1 y Q2 son hidrógeno o metilo; Z1 y Z2 son O, W' es CH2-CH2, y A1 y A2 son CH o C-CH3, entonces G-L no es tiazol o tiazol sustituido; (7) cuando Y' contiene un grupo J' seleccionado de S, S=O, SO2, NH, NR7, R2P=O, R2P=S, R2OP=O, R2NHP=O, OP=OOR2, OP=ONHR2, OSO2, NHNH, NHR6, NR6NH o N=N, W' es CR7R7' - CR7R7', y Z1 y Z2 son O, entonces G-L no es fenilo no sustituido; (8) cuando Y es NR7, W' es fenilo no sustituido o sustituido, y Q1 y Q2 son hidrógeno, entonces Z1 y Z2 no son O; (9) cuando Y' es -O-, Q1 y Q2 son hidrógeno, Z1 y Z2 son O, W' es dihidroisoxazol que contiene un grupo fenilo opcionalmente sustituido, y A1 y A2 son CH, entonces G-L es fenilo no sustituido o diclorofenilo; (10) cuando Y' es O, Q1 y Q2 son hidrógeno, Z1 y Z2 son O, W' es óxido de etileno, y A1 y A2 son CH, entonces G-L no es metilfenilo o clorofenilo; (11) cuando Y' es NR7-R7R7', W' es CR8=CR8, Q1 y Q2 son hidrógeno, A1 y A2 son CH, C-CH3, C-CH2-C6H5 o C-CH2-CH3, y Z1 y Z2 son O, entonces G-L es fenilo no sustituido, fenilo monosustituido o metilpiridinilo; (12) cuando Y' es CR7R7'-C=O, W' es NR9-CR7R7', Q1 y Q2 son hidrógeno, A1 y A2 son CH, y Z1 y Z2 son O, entonces G-L no es fenilo no sustituido, (13) cuando Y' es CHR7'-NR7 donde R7' es fenilo no sustituido, metoxi o etoxi y R7 es fenilo no sustituido, metilo o -C(O)-C6H5, W' es dimetoxifenileno o fenileno no sustituido, Z1 y Z2 son O, Q1 y Q2 son hidrógeno, y A1 y A2 son CH, C-CN, C-C(O)-C6H5 o -C(O) dimetoxifenilo, entonces G-L no es fenilo no sustituido; (14) el compuesto de fórmula (1S) no es 6,10-epitio-4H-tieno-[3',4':5,6]ciclooct[1,2-f]isoindol-7,9(5H,8H)-diona, 8-(3,5-diclorofenil)-6, 6S, 9S, 10, 11, 12-hexahidro-1, 3, 6, 10-tetrametil-2, 2, 13-trióxido, (6R, 6aR, 9aS, 10S); (15) cuando Y' es O, W' es CH2-CH2, Q1 y Q2 son metilo, Z1 y Z2 son O, y A1 y A2 son CH, entonces G-L n
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23351900P | 2000-09-19 | 2000-09-19 | |
US28473001P | 2001-04-18 | 2001-04-18 | |
US28443801P | 2001-04-18 | 2001-04-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR035340A1 true AR035340A1 (es) | 2004-05-12 |
Family
ID=27398441
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP010103101A AR035340A1 (es) | 2000-09-19 | 2001-06-28 | Compuestos de succinimida heterociclicos fusionados y analogos de los mismos, las composiciones farmaceuticas que los contienen y metodos para preparar dichos compuestos |
Country Status (36)
Country | Link |
---|---|
US (1) | US20040176324A1 (es) |
EP (1) | EP1319007B9 (es) |
JP (1) | JP4966477B2 (es) |
KR (1) | KR100765670B1 (es) |
CN (2) | CN1995039A (es) |
AR (1) | AR035340A1 (es) |
AT (1) | ATE318822T1 (es) |
AU (2) | AU6994301A (es) |
BG (1) | BG107675A (es) |
BR (1) | BR0113980A (es) |
CA (1) | CA2423071A1 (es) |
CZ (1) | CZ2003780A3 (es) |
DE (1) | DE60117551T2 (es) |
DK (1) | DK1319007T3 (es) |
EE (1) | EE200300108A (es) |
ES (1) | ES2260244T3 (es) |
GE (1) | GEP20074144B (es) |
HK (1) | HK1054230B (es) |
HR (1) | HRP20030305B9 (es) |
HU (1) | HUP0400455A3 (es) |
IL (1) | IL155019A0 (es) |
IS (1) | IS6750A (es) |
MX (1) | MXPA03002412A (es) |
MY (1) | MY138531A (es) |
NO (1) | NO329931B1 (es) |
NZ (1) | NZ524803A (es) |
PE (1) | PE20020729A1 (es) |
PL (1) | PL361707A1 (es) |
PT (1) | PT1319007E (es) |
SK (1) | SK4982003A3 (es) |
TW (1) | TWI305208B (es) |
UA (1) | UA78686C2 (es) |
UY (1) | UY26808A1 (es) |
WO (1) | WO2002024702A1 (es) |
YU (1) | YU20003A (es) |
ZA (1) | ZA200302963B (es) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040077605A1 (en) * | 2001-06-20 | 2004-04-22 | Salvati Mark E. | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
IL152719A0 (en) * | 2000-06-28 | 2003-06-24 | Bristol Myers Squibb Co | Selective androgen receptor modulators and methods for their identification |
EP1854798A3 (en) * | 2000-09-19 | 2007-11-28 | Bristol-Myers Squibb Company | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
US20040087548A1 (en) * | 2001-02-27 | 2004-05-06 | Salvati Mark E. | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
AU2002364082A1 (en) * | 2001-12-19 | 2003-07-09 | Bristol-Myers Squibb Company | Fused heterocyclic compounds and analogs thereof: modulators of nuclear hormone receptor function |
TWI263640B (en) * | 2001-12-19 | 2006-10-11 | Bristol Myers Squibb Co | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
AU2002950217A0 (en) | 2002-07-16 | 2002-09-12 | Prana Biotechnology Limited | 8- Hydroxy Quinoline Derivatives |
CN1688527A (zh) | 2002-08-12 | 2005-10-26 | 武田药品工业株式会社 | 稠合的苯衍生物以及用途 |
JP2007505164A (ja) * | 2003-06-10 | 2007-03-08 | スミスクライン ビーチャム コーポレーション | アンドロゲン、グルココルチコイド、ミネラルコルチコイドおよびプロゲステロン受容体のモジュレーターとしての1−アミノナフタレン類 |
US7378426B2 (en) | 2004-03-01 | 2008-05-27 | Bristol-Myers Squibb Company | Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 |
US7417040B2 (en) * | 2004-03-01 | 2008-08-26 | Bristol-Myers Squibb Company | Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 |
US7709516B2 (en) | 2005-06-17 | 2010-05-04 | Endorecherche, Inc. | Helix 12 directed non-steroidal antiandrogens |
WO2007015567A1 (ja) * | 2005-08-01 | 2007-02-08 | Takeda Pharmaceutical Company Limited | 環状アミン化合物 |
JPWO2008007664A1 (ja) * | 2006-07-11 | 2009-12-10 | 武田薬品工業株式会社 | 二環性複素環化合物およびその用途 |
US9284345B2 (en) | 2007-04-12 | 2016-03-15 | Endorecherche, Inc. | 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators |
US20120135997A1 (en) | 2009-07-17 | 2012-05-31 | Shionogi & Co., Ltd. | Pharmaceutical composition comprising a lactam or benzenesulfonamide compound |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
ES2885523T3 (es) | 2011-11-23 | 2021-12-14 | Therapeuticsmd Inc | Formulaciones y terapias de reposición hormonal de combinación naturales |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US9682960B2 (en) | 2013-12-19 | 2017-06-20 | Endorecherche, Inc. | Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety |
RU2016143081A (ru) | 2014-05-22 | 2018-06-26 | Терапьютиксмд, Инк. | Натуральные комбинированные гормонозаместительные составы и терапии |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
US9931349B2 (en) | 2016-04-01 | 2018-04-03 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
US11649234B2 (en) | 2018-06-14 | 2023-05-16 | The University Of Florida Research Foundation, Inc. | Nonmuscle myosin II inhibitors for substance use relapse |
US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
WO2022061226A1 (en) * | 2020-09-19 | 2022-03-24 | Augusta University Research Institute, Inc. | Compositions and methods for inhibiting trem-1 |
CN115340483A (zh) * | 2022-08-31 | 2022-11-15 | 南京吉星生物技术开发有限公司 | 一种萘基吡咯啉二酮化合物及其制备方法与它的用途 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3261845A (en) * | 1964-07-14 | 1966-07-19 | Dow Chemical Co | N-phenyl derivatives of 3,6-epoxyhexahydrophthalimide |
JPS5046697A (es) * | 1973-08-20 | 1975-04-25 | ||
US5539126A (en) * | 1994-04-20 | 1996-07-23 | Bristol-Myers Squibb Company | Method for preparing homochiral maleimide intermediates, via silylation techniques |
EP1382597A3 (en) * | 1994-12-22 | 2004-04-07 | Ligand Pharmaceuticals, Inc. | Steroid receptor modulator compounds and methods |
DE69709752T2 (de) * | 1996-06-27 | 2002-07-18 | Ligand Pharm Inc | Androgen rezeptor modulator verbindungen und verfahren |
WO1998049555A1 (en) * | 1997-04-29 | 1998-11-05 | The Salk Institute For Biological Studies | Methods for identifying ligands for nuclear hormone receptors |
US7101681B1 (en) * | 1997-11-21 | 2006-09-05 | Amgen, Inc. | Nuclear hormone receptor drug screens |
US7019026B1 (en) * | 1999-09-10 | 2006-03-28 | Novo Nordisk A/S | Modulators of Protein Tyrosine Phosphatases (PTPases) |
IL152719A0 (en) * | 2000-06-28 | 2003-06-24 | Bristol Myers Squibb Co | Selective androgen receptor modulators and methods for their identification |
-
2001
- 2001-06-20 SK SK498-2003A patent/SK4982003A3/sk unknown
- 2001-06-20 CN CNA200710006341XA patent/CN1995039A/zh active Pending
- 2001-06-20 IL IL15501901A patent/IL155019A0/xx unknown
- 2001-06-20 AU AU6994301A patent/AU6994301A/xx active Pending
- 2001-06-20 ES ES01948503T patent/ES2260244T3/es not_active Expired - Lifetime
- 2001-06-20 WO PCT/US2001/019655 patent/WO2002024702A1/en active IP Right Grant
- 2001-06-20 DK DK01948503T patent/DK1319007T3/da active
- 2001-06-20 KR KR1020037004018A patent/KR100765670B1/ko not_active IP Right Cessation
- 2001-06-20 AU AU2001269943A patent/AU2001269943B2/en not_active Ceased
- 2001-06-20 JP JP2002529112A patent/JP4966477B2/ja not_active Expired - Fee Related
- 2001-06-20 NZ NZ524803A patent/NZ524803A/en unknown
- 2001-06-20 HU HU0400455A patent/HUP0400455A3/hu unknown
- 2001-06-20 CZ CZ2003780A patent/CZ2003780A3/cs unknown
- 2001-06-20 MX MXPA03002412A patent/MXPA03002412A/es active IP Right Grant
- 2001-06-20 AT AT01948503T patent/ATE318822T1/de active
- 2001-06-20 GE GE5206A patent/GEP20074144B/en unknown
- 2001-06-20 DE DE60117551T patent/DE60117551T2/de not_active Expired - Lifetime
- 2001-06-20 BR BR0113980-0A patent/BR0113980A/pt not_active IP Right Cessation
- 2001-06-20 PT PT01948503T patent/PT1319007E/pt unknown
- 2001-06-20 PL PL36170701A patent/PL361707A1/xx unknown
- 2001-06-20 EE EEP200300108A patent/EE200300108A/xx unknown
- 2001-06-20 CN CNB018189350A patent/CN1307181C/zh not_active Expired - Fee Related
- 2001-06-20 CA CA002423071A patent/CA2423071A1/en not_active Abandoned
- 2001-06-20 YU YU20003A patent/YU20003A/sh unknown
- 2001-06-20 US US09/885,381 patent/US20040176324A1/en not_active Abandoned
- 2001-06-20 UA UA2003043564A patent/UA78686C2/uk unknown
- 2001-06-20 EP EP01948503A patent/EP1319007B9/en not_active Expired - Lifetime
- 2001-06-27 TW TW090115632A patent/TWI305208B/zh not_active IP Right Cessation
- 2001-06-28 UY UY26808A patent/UY26808A1/es not_active Application Discontinuation
- 2001-06-28 MY MYPI20013097A patent/MY138531A/en unknown
- 2001-06-28 AR ARP010103101A patent/AR035340A1/es unknown
- 2001-08-22 PE PE2001000656A patent/PE20020729A1/es not_active Application Discontinuation
-
2003
- 2003-03-18 IS IS6750A patent/IS6750A/is unknown
- 2003-03-19 NO NO20031266A patent/NO329931B1/no not_active IP Right Cessation
- 2003-03-26 BG BG107675A patent/BG107675A/bg unknown
- 2003-04-15 ZA ZA200302963A patent/ZA200302963B/en unknown
- 2003-04-18 HR HR20030305A patent/HRP20030305B9/xx not_active IP Right Cessation
- 2003-09-09 HK HK03106433.9A patent/HK1054230B/zh not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR035340A1 (es) | Compuestos de succinimida heterociclicos fusionados y analogos de los mismos, las composiciones farmaceuticas que los contienen y metodos para preparar dichos compuestos | |
AR037950A1 (es) | Compuestos de succinimida heterociclicos, fusionados y analogos de los mismos, moduladores de la funcion del receptor de la hormona nuclear | |
RU2394826C2 (ru) | Дизамещенные пиразолобензодиазепины, используемые в качестве ингибиторов cdk2 и ангиогенеза, а также для лечения злокачественных новообразований молочной железы, толстого кишечника, легкого и предстательной железы | |
AR030186A1 (es) | Compuesto antibacteriano 3-aminoquinazolina-2,4-diona, composicion farmaceutica que lo comprende y su uso para fabricarla | |
ES2598118T3 (es) | Compuestos de oxazolidin-2-ona y usos de los mismos como inhibidores de PI3Ks | |
ES2622881T3 (es) | Compuestos de N-heteroarilo | |
AR054090A1 (es) | Derivados de quinuclidina como antagonistas del receptor muscarinico m3. composiciones farmaceuticas y proceso de obtencion | |
UA72917C2 (en) | Cyclic carbamates derivatives, pharmaceutical composition containing said derivatives of cyclic carbamates and active ingredients as modulators of the progesterone receptor | |
NO20072116L (no) | Farmasoytiske forbindelser | |
RU2011117412A (ru) | Трициклические оксазолидиноновые антибиотические соединения | |
AR035759A1 (es) | Compuestos acilurea antagonistas de la funcion mpc-1, un procedimiento para su preparacion, composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos | |
YU31303A (sh) | Jedinjenja imidazola sa pripojenim arilom ili heteroarilom kao anti-inflamatorni i analgetički agensi | |
MX2008010187A (es) | Tratamiento de distrofia muscular de duchenne. | |
DK0442820T3 (da) | Benzimidazol- og azabenzimidazolderivater, som er thromboxan-receptor-antagonister, fremgangsmåder til deres fremstilling, syntesemellemprodukter og farmaceutiske præparater med indhold deraf | |
AR049331A1 (es) | Derivados de imidazopiridinas, imidazoquinolinas e iimidazonaftiridinas sustituidas con amidas como moduladores de biosintesis de citoquinas. composiciones farmaceuticas. | |
AR056613A1 (es) | Compuestos derivados de lapachona, su preparacion y metodos de uso de los mismos para el tratamiento o prevencion de trastornos proliferativos celulares y composiciones farmaceuticas que los contienen | |
IL68969A0 (en) | Urea derivatives,their preparation and herbicidal and plant growth inhibition compositions containing them | |
PE20110845A1 (es) | Nuevos compuestos heterociclicos nitrogenados, preparacion de los mismos y utilizacion de los mismos como medicamentos antibacterianos | |
PH12021551117A1 (en) | 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer | |
AU2019270089B2 (en) | Compounds for treatment of triple negative breast cancer and ovarian cancer | |
AR055431A1 (es) | Derivados del acido 4-amino-tieno[3,2-c]piridina-7-carboxilico | |
AR048808A1 (es) | Pirrolocarbazoles fusionados | |
AR052019A1 (es) | COMPUESTOS HETEROCICLICOS, PROCESOS DE PREPARACIoN Y MÉTODO PARA TRATAR ENFERMEDADES HIPERPROLIFERATIVAS | |
AR043959A1 (es) | Derivados de indolona-acetamida, procesos para prepararlos, composiciones farmaceuticas que los contienen y su uso como productos farmaceuticos | |
CA2355939A1 (en) | Antihistaminic spiro compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |